CA
ABBV icon

Clune & Associates’s AbbVie ABBV Stock Holding History

Clune & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$5.03M Buy
19,240
+207
+1% +$53.1K 0.77% 34
2026
Q2 		$4.79M Sell
19,033
-298
-2% -$64.1K 0.72% 35
2026
Q1 		$4.2M Buy
19,331
+895
+5% +$199K 0.79% 36
2025
Q4 		$4.21M Buy
18,436
+419
+2% +$95.4K 0.91% 36
2025
Q3 		$4.17M Sell
18,017
-85
-0.5% -$17.3K 1.04% 30
2025
Q2 		$3.36M Sell
18,102
-1,151
-6% -$214K 0.92% 34
2025
Q1 		$4.03M Buy
19,253
+90
+0.5% +$17.5K 1.24% 23
2024
Q4 		$3.41M Buy
+19,163
New +$3.52M 1.13% 26

Other funds holding ABBV

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Cardano Risk Management
Cardano Risk Management Rotterdam, Netherlands $18.2B AUM 38.97% 1-Year Est. Return
Hamlin Capital Management
Hamlin Capital Management New York $4.04B AUM 11.59% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Ferguson Wellman Capital Management
Ferguson Wellman Capital Management Portland, Oregon $8.38B AUM 25.07% 1-Year Est. Return
MN Services Vermogensbeheer
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
Czech National Bank
Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return
Artemis Investment Management
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return

Clune & Associates's ABBV Position: Q3 2026 in Review

Clune & Associates increased its AbbVie (ABBV) stake by 1.1% in Q3 2026, buying an estimated $53.1K and bringing the position to 19,240 shares worth $5.03M. The position accounts for 0.77% of the portfolio, ranked #34.

Clune & Associates first reported a position in ABBV in Q4 2024 and has held it in 8 quarters since. 1,096 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Clune & Associates held 19,240 shares of AbbVie worth $5.03M as of Q3 2026.
  • Clune & Associates bought 207 AbbVie shares in Q3 2026, an estimated $53.1K.
  • AbbVie made up 0.77% of Clune & Associates's portfolio in Q3 2026, its #34 holding.
  • Clune & Associates first reported a position in AbbVie in Q4 2024 and has held it in 8 quarters since.
  • 1,096 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Clune & Associates's 13F filing for Q3 2026, filed 8 Oct 2026.